ÌÇÐÄvlog

The EMBARK-HFpEF multicenter, open-label trial examines the effects of cardiac myosin inhibition with mavacamten in patients with heart failure with preserved ejection fraction with a left ventricular ejection fraction of 60% or greater.

This prespecified analysis of the Finerenone Trial to Investigate the Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial investigates the long-term effects of treatment with the nonsteroidal mineralocorticoid receptor antagonist, finerenone, in patients with heart failure with mildly reduced or preserved ejection fraction.

This essay describes the author’s experience when her father had cardiac arrest.

This post hoc analysis of a randomized clinical trial analyzes imaging data for atheroma volume at the lesion level from patients who received intensive lipid-lowering therapy with alirocumab plus statin compared with a statin alone.